A5100525784- Diabetes Treatment and Management
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Pharmaceutical studies and practices
- Metabolism, Diabetes, and Cancer
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic function and diabetes
- Drug Transport and Resistance Mechanisms
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Phosphodiesterase function and regulation
- Lung Cancer Treatments and Mutations
- Tendon Structure and Treatment
- Lower Extremity Biomechanics and Pathologies
- Foot and Ankle Surgery
- Statistical Methods in Clinical Trials
- PI3K/AKT/mTOR signaling in cancer
- Liver Diseases and Immunity
- Adrenal Hormones and Disorders
- Antibiotics Pharmacokinetics and Efficacy
- Liver Disease and Transplantation
Shandong Sport University
2024-2025
First Hospital of Jilin University
2017-2024
Jilin University
2011-2024
Dalian Medical University
2024
First Affiliated Hospital of Dalian Medical University
2024
University of Nottingham Ningbo China
2024
Northeastern University
2023
Jilin Medical University
2022
Northwest Institute of Plateau Biology
2022
John Wiley & Sons (United States)
2019
The anterior talofibular ligament (ATFL) and the calcaneofibular (CFL) are vulnerable to be torn or ruptured during lateral ankle sprain (LAS), especially in people with chronic instability (CAI). This study aims determine whether landing a larger toe-out angle would influence ATFL CFL strains CAI, aiming contribute development of effective strategies reduce LAS risk. Thirty participants CAI (22 males 8 females, age: 21.6 ± 1.5 years, height: 175.3 7.1 cm, body mass: 70.8 kg, mean SD) were...
Abstract Background GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator (class I) that can inhibit HBV replication by interfering with the and disassembly of nucleocapsid. Here, we evaluated its antiviral activity, pharmacokinetics, tolerability in double-blind, randomized, parallel, entecavir-controlled study. Methods Twenty-four patients chronic were randomized to receive 28-day course (120 or 240 mg) ritonavir (100 combination (cohorts A B, respectively) entecavir...
The meal delivery routing problem faced by the e-commerce platform is challenging. In order to reduce logistics cost and meet needs of customers, a multi-objective studied under shared services mode (SLSM). problem, third-party providers need arrange vehicles in multi-depot pick up meals from multiple food deliver them so as realize sharing between compare with traditional service (TLSM). While realizing sharing, it also necessary customer time requirements much possible. this case,...
To investigate the pharmacokinetics and pharmacodynamics of a dual-acting glucokinase activator, dorzagliatin, its safety, tolerability effect on pancreatic β-cell function in Chinese patients with type 2 diabetes (T2D).A total 24 T2D were selected, utilizing set predefined clinical biomarkers, randomized to receive dorzagliatin 75 mg twice or once daily (BID, QD respectively) for 28 days. Changes HbA1c glycaemic parameters from baseline Day assessed. In addition, changes 32...
Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were evaluated in patients with CHB.
Background: Jaktinib is a novel selective janus kinase 1/2 inhibitor. The phase I first-in-human study evaluated the tolerance and pharmacokinetics of jaktinib in healthy Chinese subjects. Methods: A randomized, double-blind, placebo-controlled were designed. total 126 subjects enrolled into single ascending dose, multiple dose food effect study. Safety endpoints included adverse events, abnormal vital signs, 12-lead ECGs, abdominal ultrasound, chest x-ray, physical examination clinical...
Objective: The aim of the study was to explore association pharmacokinetic variability and pharmacogenomics with bioequivalence orally administered gefitinib (Iressa®, AstraZeneca) provided by three sponsors in healthy subjects. Methods: designs were randomized, open-label, two-period crossover studies both fasting fed In one study, sample size enlarged from 30 60 for failing study. Each subject received a 250-mg tablet 21-day washout. plasma concentrations measured using LC-MS/MS,...
Abstract Background Recaticimab (SHR-1209, a humanized monoclonal antibody against PCSK9) showed robust LDL-C reduction in healthy volunteers. This study aimed to further assess the efficacy and safety of recaticimab patients with hypercholesterolemia. Methods In this randomized, double-blind, placebo-controlled phase 1b/2 trial, receiving stable dose atorvastatin an level 2.6 mmol/L or higher were randomized ratio 5:1 subcutaneous injections placebo at different doses schedules. Patients...
Summary Background HS‐10234 is a novel prodrug of tenofovir developed to increase anti‐viral potency and reduce systemic toxicities. Aims To evaluate the tolerability, pharmacokinetics efficacy in patients with chronic hepatitis B (CHB) infection Methods Treatment‐naïve subjects non‐cirrhotic CHB were divided into three groups (n = 12/group) randomised within each group receive 10, 25 or 40 mg HS‐10234, 300 disoproxil fumarate (TDF) once day for 28 days. Results Among 36 enrolled subjects,...
This study was conducted to explore the tolerance, variability, pharmacokinetics (PK), and pharmacodynamics (PD) of denosumab biosimilar (QL1206) in healthy Chinese subjects.This is a randomized, double-blind, two-arm, parallel performed examine bioequivalence biosimilar, QL1206, with that Xgeva® (Denosumab) as reference drug. A single dose 120 mg/kg or administered subjects, who were followed up for 134 days.Similar PK properties those exhibited by QL1206. When compared QL1206 Xgeva®, 90%...
The primary objective of this study was to investigate if hepatic impairment alters the safety, pharmacokinetics, and pharmacodynamics HSK3486.This a clinical trial HSK3486 in subjects with normal function (n = 8), mild (Child-Pugh A; n or moderate B; 8) impairment. Each subject received an IV bolus dose 0.4 mg/kg for 1 min, immediately followed by maintenance infusion mg/kg/h 30 min.In total, 24 were enrolled completed study. generally well tolerated all subjects. There no serious AEs...
Abstract The effect of age on the pharmacokinetics and safety chiglitazar was evaluated in patients < 65 ≥ years with type 2 diabetes mellitus (T2DM). A total 20 T2DM (<65 vs ≥65 1:1) completed study. Patients received multiple doses 48 mg once daily for 7 days consecutively. After first dosing, maximum plasma concentration (C max ) area under concentration‐time curve (AUC) were similar to those observed years, geometric mean ratio (GMR) C AUC being 97.22% 96.83%, respectively. No...
Iron deficiency (ID) is one of the most commonly known nutritional deficiencies and considered primary cause anemia (iron-deficiency anemia). Ferric carboxymaltose (FCM), an intravenous iron preparation, has been widely used for >10 years iron-deficiency treatment worldwide because its many advantages.This single-center, open-label, single dose escalation study in Chinese subjects was designed to assess pharmacokinetic/pharmacodynamic parameters safety FCM this population. The first 12...
TQ-A3334, a selective, oral toll-like receptor (TLR)-7 agonist, is being developed to treat chronic hepatitis B (CHB). This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TQ-A3334 in healthy participants.The effects single-ascending dose (0.2-1.8 mg) combined with food (1.2 were 48 participants.No serious adverse events or discontinuations occurred study. The most common reactions lymphocyte count decreased headache, which generally consistent IFN-α exposure...
Background Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report first clinical trial on tolerability, pharmacokinetics pharmacodynamics different doses vicagrel, comparison with in healthy Chinese volunteers. Methods This study was conducted two parts. Study I dose-escalating (5–15 mg) study. For each dose, 15 participants were randomized into three groups (total n = 45); nine given clopidogrel,...
Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806 its reference products marketed in EU and US (RoActemra-EU Actemra-US) among healthy Chinese men. tolerance, immunogenicity, pharmacokinetics (PK) three drugs were also investigated. Methods: In this randomized, double-blind, single-dose, three-arm, parallel study, single-dose 4 mg/kg products, or was administered participants. participants followed up for 57 days, PK, tolerance evaluations completed...
e14627 Background: WX390 is a high potent PI3K-mTOR dual inhibitor targeting pan-PI3K and mTOR. It modulates the tumor immune microenvironment by decreasing Treg myeloid-derived suppressor cells (MDSC) improves response to checkpoint inhibitors (CPI) in preclinical models. Methods: The Phase Ib study was designed evaluate safety, pharmacokinetics (PK), preliminary clinical activity, determine recommended phase 2 dose (RP2D) of combined with Toripalimab patients advanced solid tumors....
Psoriasis is a chronic, immune-mediated skin disease with an unmet need for biologic treatment options. To assess the safety, pharmacokinetics, and efficacy of QX004N in healthy individuals patients moderate to severe plaque psoriasis China. This randomized clinical trial was composed 2 parts. Part 1 first-in-human, single-ascending-dose, phase 1a conducted from November 2, 2021, January 16, 2023. double-blind, multiple dose-escalation, 1b February 15, 2023, 5, 2024, at 5 centers China,...